Targeted Therapy
total 11
Immuno-Oncology
total 4
KRAS pathway

KRAS G12C Inhibitor Signal pathway: RASView More

Glecirasib

Glecirasib (JAB-21822) is a KRAS G12C inhibitor independently developed by Jacobio. From the in-house preclinical head-to-head study, this compound has superior oral bioavailability and systemic drug exposure, better pharmacokinetic profiles and tolerance, and is a potential best-in-class compound.

As date of May 22, 2024

  • China
  • Global

Glecirasib

Therapy Indications Phase I Phase IIa Phase IIb Pivotal Phase III Pivotal Recent progress
Mono NSCLC
 
 
 
 

NDA accepted and granted Priority Review designation

May 2024

Mono PDAC 
 
 
 
   

BTD granted

Aug 2023

Pivotal study FPI

Oct 2023

Combo w/EGFR mAb CRC
 
 
 
 

Registrational Phase III trial approved

May 2024

Combo w/SHP2i JAB-3312 NSCLC, CRC and other solid tumors
 
 
 
 

Registrational Phase III trial approved

Feb 2024

Mono 1L NSCLC with STK11 co-mutation
 
 
 
     
Combo w/PD-1 mAb NSCLC
 
 
 
     
Mono

NSCLC、PDAC、CRC and other solid tumors

 
 
 
     

SHP2 Inhibitor Signal pathway: RAS、I/OView More

 

JAB-3068 is the second SHP2 inhibitor approved by the FDA to enter clinical development. JAB-3312, the second generation SHP2 inhibitor designed by Jacobio has more potent anti-tumor activities. Both compounds have been granted orphan drug designation by the FDA for the treatment of esophageal cancer (including esophageal squamous cell carcinoma).

As date of Feb 18, 2024
  • U.S.
  • China
  • Global

JAB-3312


Therapy Indications Phase I Phase IIa Phase III Pivotal Recent progress

KRAS G12Ci Combination Therapy

Glecirasib

KRAS G12C mut NSCLC
 
 
 
Registrational Phase III trial approved
Feb 2024
Combo w/EGFRi Osimertinib progressed NSCLC
 
 
 
  FPI
Jan 2022
Combo w/PD-1 mAb NSCLC, HNSCC, ESCC
 
 
 
  Phase IIa FPI
Feb 2022

 

 

KRASmulti Signal pathway: RAS

JAB-23E73

KRASmulti inhibitor JAB-23E73 targets multiple KRAS mutants in both RAS(ON) and RAS (OFF), with good selectivity over HRAS and NRAS.

As date of Jul 9, 2024
  • U.S.
  • China
  • Global

JAB-23E73

Modality Indications IND Phase I Phase II Recent Progress
Small molecule

PDAC, CRC, NSCLC

 
 
 

 

IND submitted
Jul 2024

Aurora A inhibitor Signal pathway: RBView More

JAB-2485

JAB-2485 is an Aurora Kinase A (AURKA) inhibitor developed independently by Jacobio Pharma. It inhibits AURKA effectively and does not affect the activity of other kinases structurally similar to AURKA, minimizing the toxicity of the drug and improving the therapeutic window.

As date of Aug 30, 2023

  • U.S.
  • China
  • Global

JAB-2485

Therapy Indications IND Phase I Phase II Recent progress
Monotherapy Solid Tumor
 
 
 

FPI in U.S.
Jan 2023

The first site in China was initiated
Aug 2023

LIF monoclonal antibodySignal pathway: RAS

JAB-BX300

JAB-BX300 is Jacobio’s self-developed LIF mAb. LIF is an important biomarker in pancreatic ductal adenocarcinoma (PDAC). Studies show that, LIF plays a crucial role in KRAS-driven cancer models and the blockade of LIF by antibodies represents an attractive approach to improving therapeutic outcomes. LIF is an attractive target for the treatment of KRAS-driven tumors, which has potential to combo with KRAS and SHP2 inhibitors.

As date of Apr 4, 2023
  • U.S.
  • China
  • Global

JAB-BX300

Therapy Indications IND Phase I Phase IIa Recent progress
Monotherapy Solid Tumor
 
 
 
IND Approved in China
Apr 2023

KRAS G12D Signal pathway: RAS

JAB-22000

JAB-22000 is a small-molecule KRAS G12D inhibitor. Currently, there is only one small molecule KRAS G12D program in the Phase I clinical stage in respective drug classes globally. Therefore, JAB-22000 has the potential to be among the first few market entrants.

As date of Mar 28, 2024

JAB-22000

Modality Indications Lead Optimization IND-enabling Recent Development IND Schedule
Small molecule

PDAC, CRC, NSCLC

 
 
 
 

Clinical candidate will be nominated in 2024. IND schedule will be adjusted according to the progress and the clinical efficacy and safety data of JAB-23E73, our KRASmulti inhibitor

MYC pathway

BET Inhibitor Signal pathway: MYC View More

JAB-8263

JAB-8263 class 1 innovative drug that is a Bromodomain and Extra-Terminal motif (BET) inhibitor independently developed by Jacobio. Preclinical studies have n that JAB-8263 can effectively inhibit tumor growth at very low concentrations. In addition to solid tumors, hematological tumors are particularly sensitive to JAB-8263. Patients with hematological tumors and some types of solid tumors may benefit from the treatment of JAB-8263.

As date of Mar 28, 2024
  • U.S.
  • China
  • Global

JAB-8263

Therapy Indications IND Phase I Phase II Recent progress
Monotherapy Solid Tumor
 
 
 

Phase II trial to be initiated in 2024 H2

Monotherapy Solid Tumor
 
 
 
Monotherapy MF, AML
 
 
 

GUE inhibitorSignal pathway: Tumor metabolism

JAB-24114

JAB-24114 is Jacobio’s self-developed GUE (glutamine-utilizing enzyme) inhibitor. Tumor growth is highly dependent on glutamine, which can be converted into various metabolites by multiple glutamine-utilizing enzymes (GUEs). These metabolites support a variety of tumor growth pathways. JAB-24114 can inhibit multiple GUEs, leading to simultaneous blockade of multiple glutamine metabolism pathways, with great therapeutic potential. Compared with its similar product, JAB-24114 has a wider therapeutic window. JAB-24114 has the distinctive combination effects of depleting tumors of nutrients while enhancing T cell function. Synergistic action with anti-PD-(L)1 can boost the anti-tumor effect. JAB-24114 can also be used in combination with SHP2 inhibitors or KRAS inhibitors.

As date of Mar 17, 2023
  • U.S.
  • China
  • Global

JAB-24114

Therapy Indications IND Phase I Phase IIa Recent progress
Monotherapy Solid Tumor
 
 
 
IND Approved in China
Mar 2023

Aurora A inhibitor Signal pathway: RBView More

JAB-2485

JAB-2485 is an Aurora Kinase A (AURKA) inhibitor developed independently by Jacobio Pharma. It inhibits AURKA effectively and does not affect the activity of other kinases structurally similar to AURKA, minimizing the toxicity of the drug and improving the therapeutic window.

As date of Aug 30, 2023

  • U.S.
  • China
  • Global

JAB-2485

Therapy Indications IND Phase I Phase II Recent progress
Monotherapy Solid Tumor
 
 
 

FPI in U.S.
Jan 2023

The first site in China was initiated
Aug 2023

P53 pathway

P53 Y220C Signal pathway: P53View More

JAB-30355

JAB-30355 is an orally bioavailable small molecule activator for the treatment of patients with locally advanced or metastatic solid tumors harboring P53 Y220C mutation. Studies shows that, JAB-30355 has shown very high binding affinity to P53 Y220C mutant proteins. Tumor regression was achieved in multiple cancer models covering various tumor types, such as gastric cancer, ovarian cancer, breast cancer and lung cancer. The synergistic effect was found when combined with chemo or oncogenic protein inhibitors which indicates a widely combo potential of JAB-30355.

As date of Jul 4 2024
  • U.S.
  • China
  • Global

JAB-30355

Modality Indications IND Phase I Phase IIa Recent progress
Small molecule

Solid tumors

 
 
 
 

IND Approved in U.S.
Mar 2024

IND Approved in China
Jun 2024

GUE inhibitorSignal pathway: Tumor metabolism

JAB-24114

JAB-24114 is Jacobio’s self-developed GUE (glutamine-utilizing enzyme) inhibitor. Tumor growth is highly dependent on glutamine, which can be converted into various metabolites by multiple glutamine-utilizing enzymes (GUEs). These metabolites support a variety of tumor growth pathways. JAB-24114 can inhibit multiple GUEs, leading to simultaneous blockade of multiple glutamine metabolism pathways, with great therapeutic potential. Compared with its similar product, JAB-24114 has a wider therapeutic window. JAB-24114 has the distinctive combination effects of depleting tumors of nutrients while enhancing T cell function. Synergistic action with anti-PD-(L)1 can boost the anti-tumor effect. JAB-24114 can also be used in combination with SHP2 inhibitors or KRAS inhibitors.

As date of Mar 17, 2023
  • U.S.
  • China
  • Global

JAB-24114

Therapy Indications IND Phase I Phase IIa Recent progress
Monotherapy Solid Tumor
 
 
 
IND Approved in China
Mar 2023
iADC

CD73-STING iADC Signal pathway: I/O

JAB-BX500

JAB-BX500 is the world's first iADC by conjugating Jacobio’s STING agonist to CD73 antibody, which is expected to turn the tumor from "cold" to "hot".

As date of Mar 28, 2024

JAB-BX500

Modality Indications Lead Optimization IND-enabling Recent Development IND Schedule
Small molecule

Solid tumors

 
 
 
Candidate nominated in 2023 Q1

2025 IND

HER2-STING iADC Signal pathway: I/O

JAB-BX400

Our HER2-STING iADC showed excellent features in pre-clinical studies, including favorable physicochemical properties at even high drug to antibody ratio value, hundreds to thousands fold improvement in activity over the free STING payload, and complete and durable tumor regression with only single dose in SK-OV-3 CDX model.

As date of Mar 28, 2024

JAB-BX400

Modality Indications Lead Optimization IND-enabling Recent Development IND Schedule
Small molecule

Solid tumors

 
 
 
Clinical candidate to be nominated in 2024 H2

2025 IND

STING downstream targets

PARP7 inhibitorSignal pathway: I/O

JAB-26766

JAB-BX300 is Jacobio’s self-developed PARP7 inhibitor. PARP7 inhibitors target I/O (immuno-oncology) signaling pathway and can be used to treat various solid tumors such as squamous NSCLC, and HNSCC. Studies show that, PARP7 inhibitors have the potential to directly inhibit tumor growth and enhance the anti-tumor immune response.

As date of Jun 8, 2023
  • U.S.
  • China
  • Global

JAB-26766

Therapy Indications IND Phase I Phase IIa Recent progress
Monotherapy Solid Tumor
 
 
 
IND Approved in China
Jun 2023

CD73 monoclonal antibody Signal pathway: I/OView More

JAB-BX102

JAB-BX102 is a humanized anti-CD73 monoclonal antibody (mAb)developed by Jacobio to inhibit the enzymatic activity of CD73. CD73 is the key node of adenosine pathway, and its inhibitors have broad therapeutic prospects for tumors dependent on adenosine pathway. Relevant studies have shown that adenosine promotes SHP2 phosphorylation, suggesting that anti-CD73 antibody can be combined with SHP2 inhibitor, which is also developed by Jacobio to benefit patients with advanced solid tumors.

As date of Aug 30, 2023

  • U.S.
  • China
  • Global

JAB-BX102

Therapy Indications IND Phase I Phase IIa Recent progress
Mono and Combo w/ PD-1 antibody Solid Tumor
 
 
 

RP2D to be determined in 2024 H1

Abbreviation: mAb = monoclonal antibody; ESCC = esophageal squamous cell carcinoma; HNSCC = head and neck squamous cell carcinoma; NSCLC = non-small cell lung cancer; KRAS amp = KRAS amplification; LOF = loss of function; CRC = colorectal cancer; MF = myelofibrosis; AML = acute myeloid leukemia; CRPC = castration resistant prostate cancer; HCC = hepatocellular carcinoma; PDAC = pancreatic ductal adenocarcinoma; IND = investigational new drug.

As date of Jun 8, 2023